Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 – Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth

Publisher Name :
Date: 15-Dec-2013
No. of pages: 106

GBI Research has released the pharma report “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract. They are often diagnosed at advanced, incurable stages due to a late onset of symptoms, but are also associated with low survival rates in the early stages of disease.

Currently the primary treatment options are chemotherapy and surgery, which are used wherever possible. One monoclonal Antibody (mAb), Herceptin (trastuzumab) is marketed for use in suitable patients with advanced gastric or gastro-esophageal junction cancer.

However, the late-stage pipelines for these indications include many promising mAb candidates which are anticipated to enter the market during the forecast period. Additionally, current market conditions are favorable for new mAbs, with high pricing patterns and weak impact from biosimilar exposure. As a result of this, GBI Research believes the global market has the potential to grow to a value of $766m by 2019.

Scope

  • A brief introduction to the two indications, including the disease’s pathogenesis, risk factors, diagnosis and treatment algorithms.
  • In-depth analysis of Herceptin, including analysis of its safety, efficacy, treatment patterns and strengths/weaknesses.
  • A comprehensive review of the pipeline for mAbs in gastric and esophageal cancer, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
  • Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.
  • Multi-scenario forecast data of the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Canada, Japan, Germany, the UK, France, Italy and Spain.
  • Discussion of the drivers and barriers for market growth.

Reasons to buy

  • Understand the unmet need in the treatment of these cancers, the role of Herceptin and the areas of opportunity for other mAbs to enter the market.
  • Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
  • Observe the trends in clinical trial duration, size and molecule types across the phases of development and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for mAbs in gastric and esophageal cancers.
  • Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs.
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the market for mAbs in gastric and esophageal cancers.

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 – Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7

2 Introduction 9
2.1 Symptoms 9
2.1.1 Early Gastric Cancer 9
2.1.2 Early Esophageal Cancer 10
2.1.3 Advanced Gastric or Esophageal Cancer 10
2.2 Etiology 10
2.2.1 Esophageal Cancer 10
2.2.2 Gastric Cancer 11
2.3 Epidemiology 11
2.4 Pathophysiology 12
2.5 Diagnosis 13
2.6 Prognosis and Disease Staging 13
2.7 Treatment Options 16
2.7.1 Chemotherapy 16
2.7.2 Targeted Therapies 16
2.7.3 Treatment Guidelines 17
2.7.4 Resistance to Pharmacological Therapies 19

3 Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019- Marketed Products 20
3.1 Herceptin (Trastuzumab) - Hoffman La Roche 20

4 Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019- Developmental Pipeline 22
4.1 Gastric Cancer 22
4.1.1 Overall Pipeline 22
4.1.2 Molecular Targets 24
4.1.3 Clinical Trials 26
4.1.4 Conclusion 33
4.2 Esophageal Cancer 34
4.2.1 Overall Pipeline 34
4.2.2 Molecular Targets 36
4.2.3 Clinical Trials 37
4.2.4 Conclusion 43
4.3 Key Late-Stage Pipeline Products 43
4.3.1 AMG 102 (rilotumumab) - Amgen 43
4.3.2 IMC-1121B (Ramucirumab) - Eli Lilly and Company 43
4.3.3 Theraloc (Nimotuzumab) - YM Biosciences 44
4.3.4 MetMAb (Onartuzumab) - F. Hoffmann-La Roche 44
4.3.5 Perjeta (pertuzumab) - F. Hoffmann-La Roche 44
4.3.6 Kadcyla (ado-trastuzumab emtansine) - F. Hoffmann-La Roche 45
4.4 Conclusion 46

5 Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019- Market Forecast to 2019 47
5.1 Gastric Cancer 48
5.1.1 Global 48
5.1.2 US 51
5.1.3 Canada 53
5.1.4 Europe 55
5.1.5 Japan 58
5.2 Esophageal Cancer 60
5.2.1 Global 60
5.2.2 US 62
5.2.3 Canada 64
5.2.4 Europe 66
5.2.5 Japan 69
5.3 Drivers and Barriers 70
5.3.1 Drivers 70
5.3.2 Barriers 72

6 Deals and Strategic Consolidations 74
6.1 Licensing Agreements 74
6.1.1 Gastric Cancer 74
6.1.2 Esophageal Cancer 77
6.2 Co-Development Agreements 77
6.2.1 Gastric Cancer 77
6.2.2 Esophageal Cancer 78

7 Appendix 79
7.1 Market Definitions 79
7.2 Abbreviations 79
7.3 References 80
7.4 All Pipeline Products, by Stage of Development 84
7.4.1 Gastric Cancer 84
7.4.2 Esophageal Cancer 93
7.5 Tabular Forecast Data 97
7.5.1 Gastric Cancer 97
7.5.2 Esophageal Cancer 100
7.6 Research Methodology 102
7.6.1 Coverage 102
7.6.2 Secondary Research 103
7.6.3 Therapeutic Landscape 103
7.6.4 Epidemiology-Based forecasting 103
7.6.5 Market Size by Geography 105
7.6.6 Geographical Landscape 106
7.6.7 Pipeline Analysis 106
7.6.8 Competitive Landscape 106
7.6.9 Expert Panel Validation 106
7.7 Contact Us 106
7.8 Disclaimer 106

List of Tables

Table 1: Market for mAbs in Gastrointestinal Tract Cancer, US, Epidemiology, 2008 11
Table 2: Market for mAbs in Gastrointestinal Tract Cancer, US, Diagnosis by Stage, 2008 12
Table 3: Market for mAbs in Gastrointestinal Tract Cancer, US, Five-Year Relative Survival by Stage, 2003-2009 14
Table 4: Market for mAbs in Gastric Cancer, Global, TNM Staging, 2010-2013 15
Table 5: Gastric Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 84
Table 6: Gastric Cancer Therapeutics, Global, All Pipeline Products (Preclinical and IND/CTA-filed), 2013 85
Table 7: Gastric Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2013 87
Table 8: Gastric Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 89
Table 9: Gastric Cancer Therapeutics, Global, All Pipeline Products (Phase III and Pre-registration), 2013 92
Table 10: Gastric Cancer Therapeutics, Global, All Pipeline Products (Undisclosed), 2013 93
Table 11: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 93
Table 12: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Preclinical and IND/CTA-filed), 2013 94
Table 13: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2013 94
Table 14: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 95
Table 15: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Phase III and Pre-registration), 2013 97
Table 16: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Undisclosed), 2013 97
Table 17: Market for mAbs in Gastric Cancer, Global, Forecast Data, 2012-2019 97
Table 18: Market for mAbs in Gastric Cancer, US, Forecast Data, 2012-2019 98
Table 19: Market for mAbs in Gastric Cancer, Canada, Forecast Data, 2012-2019 98
Table 20: Market for mAbs in Gastric Cancer, UK, Forecast Data, 2012-2019 98
Table 21: Market for mAbs in Gastric Cancer, France, Forecast Data, 2012-2019 98
Table 22: Market for mAbs in Gastric Cancer, Germany, Forecast Data, 2012-2019 99
Table 23: Market for mAbs in Gastric Cancer, Italy, Forecast Data, 2012-2019 99
Table 24: Market for mAbs in Gastric Cancer, Spain, Forecast Data, 2012-2019 99
Table 25: Market for mAbs in Gastric Cancer, Japan, Forecast Data, 2012-2019 99
Table 26: Market for mAbs in Esophageal Cancer, Global, Forecast Data, 2012-2019 100
Table 27: Market for mAbs in Esophageal Cancer, US, Forecast Data, 2012-2019 100
Table 28: Market for mAbs in Esophageal Cancer, Canada, Forecast Data, 2012-2019 100
Table 29: Market for mAbs in Esophageal Cancer, UK, Forecast Data, 2012-2019 101
Table 30: Market for mAbs in Esophageal Cancer, France, Forecast Data, 2012-2019 101
Table 31: Market for mAbs in Esophageal Cancer, Germany, Forecast Data, 2012-2019 101
Table 32: Market for mAbs in Esophageal Cancer, Italy, Forecast Data, 2012-2019 101
Table 33: Market for mAbs in Esophageal Cancer, Spain, Forecast Data, 2012-2019 102
Table 34: Market for mAbs in Esophageal Cancer, Japan, Forecast Data, 2012-2019 102

List of Figures

Figure 1: Gastric Cancer: Treatment Algorithm 17
Figure 2: Esophageal Cancer: Treatment Algorithm (Locoregional Tumor) 18
Figure 3: Market for mAbs in Gastrointestinal Tract Cancer, Global, Sales of Herceptin ($bn), 1999-2012 20
Figure 4: Market for mAbs in Gastric Cancer, Global, Overall Pipeline, 2013 23
Figure 5: Market for mAbs in Gastric Cancer, Global, Pipeline mAbs by Mechanism of Action and Molecular Target, 2013 25
Figure 6: Market for mAbs in Gastric Cancer, Global, Developmental Pipeline Failure Rate, 2006-2013 26
Figure 7: Market for mAbs in Gastric Cancer, Global, Clinical Trial Sizes, 2006-2013 27
Figure 8: Market for mAbs in Gastric Cancer, Global, Clinical Trial Sizes by Molecule Type, 2006-2013 28
Figure 9: Market for mAbs in Gastric Cancer, Global, Clinical Trial Durations, 2006-2013 29
Figure 10: Market for mAbs in Gastric Cancer, Global, Clinical Trial Durations by Molecule Type, 2006-2013 30
Figure 11: Market for mAbs in Gastric Cancer, Global, Clinical Trial Primary Endpoints (All Molecule Types), 2006-2013 31
Figure 12: Market for mAbs in Gastric Cancer, Global, Clinical Trial Primary Endpoints (mAbs Only), 2006-2013 32
Figure 13: Market for mAbs in Gastric Cancer, Global, Clinical Trial Primary Endpoints by Developmental Program (mAbs Only), 2006-2013 33
Figure 14: Market for mAbs in Esophageal Cancer, Global, Overall Pipeline, 2013 35
Figure 15: Market for mAbs in Esophageal Cancer, Global, Pipeline mAbs by Mechanism of Action, 2013 36
Figure 16: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Sizes, 2006-2013 37
Figure 17: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Sizes by Molecule Type, 2006-2013 38
Figure 18: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Durations, 2006-2013 39
Figure 19: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Durations by Molecule Type, 2006-2013 40
Figure 20: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Primary Endpoints (All Molecule Types), 2006-2012 41
Figure 21: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Primary Endpoints (mAbs Only), 2006-2012 42
Figure 22: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Primary Endpoints by Developmental Program (mAbs Only), 2006-2012 42
Figure 23: Market for mAbs in Gastric Cancer, Global, Market Size and Growth, 2012-2019 47
Figure 24: Market for mAbs in Esophageal Cancer, Global, Market Size and Growth, 2012-2019 48
Figure 25: Market for mAbs in Gastric Cancer, Global, Treatment Usage Patterns, 2012-2019 49
Figure 26: Market for mAbs in Gastric Cancer, Global, Market Size ($m), 2012-2019 50
Figure 27: Market for mAbs in Gastric Cancer, US, Treatment Patterns, 2012-2019 51
Figure 28: Market for mAbs in Gastric Cancer, US, Market Size ($m), 2012-2019 52
Figure 29: Market for mAbs in Gastric Cancer, Canada, Treatment Usage Patterns, 2012-2019 53
Figure 30: Market for mAbs in Gastric Cancer, Canada, Market Size ($m), 2012-2019 54
Figure 31: Market for mAbs in Gastric Cancer, Top Five European Markets, Treatment Usage Patterns, 2012-2019 55
Figure 32: Market for mAbs in Gastric Cancer, Top Five European Markets, Annual Cost of Therapy, 2012-2019 56
Figure 33: Market for mAbs in Gastric Cancer, Top Five European Markets, Market Size ($m), 2012-2019 57
Figure 34: Market for mAbs in Gastric Cancer, Japan, Treatment Usage Patterns, 2012-2019 59
Figure 35: Market for mAbs in Gastric Cancer, Japan, Market Size ($m), 2012-2019 60
Figure 36: Market for mAbs in Esophageal Cancer, Global, Treatment Usage Patterns, 2012-2019 61
Figure 37: Market for mAbs in Esophageal Cancer, Global, Market Size ($m), 2012-2019 61
Figure 38: Market for mAbs in Esophageal Cancer, US, Treatment Patterns, 2012-2019 62
Figure 39: Market for mAbs in Esophageal Cancer, US, Market Size ($m), 2012-2019 63
Figure 40: Market for mAbs in Esophageal Cancer, Canada, Treatment Patterns, 2012-2019 64
Figure 41: Market for mAbs in Esophageal Cancer, Canada, Market Size ($m), 2012-2019 65
Figure 42: Market for mAbs in Esophageal Cancer, Top Five European Markets, Treatment Usage Patterns, 2012-2019 66
Figure 43: Market for mAbs in Esophageal Cancer, Top Five European Markets, Annual Cost of Therapy ($), 2012-2019 67
Figure 44: Market for mAbs in Esophageal Cancer, Top Five European Markets, Market Size ($m), 2012-2019 68
Figure 45: Market for mAbs in Esophageal Cancer, Japan, Treatment Patterns, 2012-2019 69
Figure 46: Market for mAbs in Esophageal Cancer, Japan, Market Size ($m), 2012-2019 70
Figure 47: Market for mAbs in Gastric Cancer, Global, Licensing Deals (Countries), 2006-2013 74
Figure 48: Market for mAbs in Gastric Cancer, Global, Licensing Deals by Year and Value, 2006-2013 75
Figure 49: Market for mAbs in Gastrointestinal Tract Cancers, Global, Licensing Deals, 2006-2013 75
Figure 50: Market for mAbs in Gastric Cancer, Global, Co-Development Deals, 2006-2013 77
Figure 51: GBI Research Market Forecasting Model 105

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Antibody Deals and Alliances of 2013
    Published: 1-Aug-2014        Price: US $1495 Onwards        Pages: 200
    "Delivery of this report will take 1-3 days after purchase." The Antibody Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced wo......
  • Research on China Monoclonal Antibody (McAB) Industry, 2014
    Published: 1-Jul-2014        Price: US $2000 Onwards        Pages: 60
    "Please Note: The report is in Chinese version now. The English version will be delivered in 1-2 business days." Research on China Monoclonal Antibody (McAB) Industry, 2014 mainly carries on in-depth analysis on policy environment, global market, Chinese market, as well as the latest developments of domestic key enterprises related to China's monoclonal antibody industry. Several Chinese large-scale pharmaceutical enterprises devoted themselves to research and development of monoclonal ant......
  • Global and China Monoclonal Antibody Industry Report, 2013-2017
    Published: 23-Dec-2013        Price: US $2500 Onwards        Pages: 118
    Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period. Thanks to robust market demand, approval of new products and new indications as well as launch of monoclonal antibody generic drugs, the global monoclonal......
  • Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth
    Published: 15-Dec-2013        Price: US $3500 Onwards        Pages: 89
    GBI Research, has released the pharma report “Monoclonal Antibodies Market in Colorectal Cancer to 2019 Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient’s lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin, which generated revenues of $6.2 billion in 2012 across a num......
  • Patrys Limited – Product Pipeline Review – 2013
    Published: 30-Sep-2013        Price: US $1500 Onwards        Pages: 49
    Global Market Direct's pharmaceuticals report, "Patrys Limited Product Pipeline Review 2013" provides data on the Patrys Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct's proprietary databases, Patrys Limited's corporate website, SEC filings, investor presentations and fe......
  • Research Report on Global and China Monoclonal Antibody Industry, 2013-2017
    Published: 2-Aug-2013        Price: US $2200 Onwards        Pages: 50
    Antibody drugs are usually generated from monoclonal antibody through genetic engineering, with the advantages of strong targeting, few side effects, etc. With rather promising application prospect in clinic treatment, antibody drugs are mainly applied in curing diseases like tumour, immune system and so on. In terms of the global market, antibody drugs account for over 40% of the entire biotech drug market and the market share still keeps increasing. Antibody drugs have become one of the most i......
  • Monoclonal Antibody Markets in China
    Published: 1-May-2013        Price: US $4000 Onwards        Pages: 187
    China's demand for monoclonal antibody has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.......
  • Synagis (Pediatric RSV) – Forecast and Market Analysis to 2022
    Published: 30-Apr-2013        Price: US $3495 Onwards        Pages: 48
    GlobalData has released its new PharmaPoint Drug Evaluation report, “Synagis (Pediatric RSV) Forecast and Market Analysis to 2022”. Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread through the air by an infected person’s sneeze or cough, or through direct and indirect contac......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs